Treatment of Cancer-associated Anorexia Using Megestrol Acetate Concentrated Suspension

PHASE3TerminatedINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

June 30, 2006

Primary Completion Date

September 30, 2006

Study Completion Date

September 30, 2006

Conditions
AnorexiaCachexiaWeight Loss
Interventions
DRUG

Megestrol acetate concentrated suspension 110 mg/mL

Megestrol acetate concentrated suspension 110 mg/mL given as an oral dose of 550 mg (5 mL) once per day for 56 days, with an optional 28 days extension phase

DRUG

Megestrol acetate concentrated suspension 60 mg/mL

Megestrol acetate concentrated suspension 60 mg/mL given as an oral dose of 300 mg (5 mL) once per day for 56 days, with an optional 28 days extension phase

DRUG

Placebo

Placebo oral suspension, 5 mL once daily

Trial Locations (4)

27262

Wake Forest University, High Point

28731

Four Seasons Hospice and Paliative Care, Flat Rock

44304

Summit Oncology Associates, Inc., Akron

92801

Pacific Cancer Medical Center, Inc., Anaheim

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

PRA Health Sciences

INDUSTRY

lead

Par Pharmaceutical, Inc.

INDUSTRY

NCT00637806 - Treatment of Cancer-associated Anorexia Using Megestrol Acetate Concentrated Suspension | Biotech Hunter | Biotech Hunter